Nasdaq:CMPX
Compass Therapeutics, Inc.
A pre-revenue clinical-stage biotech firm specializing in small molecule drug discovery for oncology and immunology indications.
Key Metrics
Investment Thesis
Bull Case
Investors may view Compass Therapeutics as an attractive speculative opportunity given its large cash reserves relative to annual burn rate, providing a long runway to advance its pipeline. The company's focus on oncology and immunology targets offers high asymmetry potential, with the possibility of multi-billion dollar value creation if key assets achieve regulatory approval. Strong financing capabilities demonstrated through recent issuances suggest management can fund operations without immediate distress.
Bear Case
The absence of approved products and consistent widening losses make the stock highly vulnerable to market volatility and funding dry-ups. With operating expenses exceeding $57M annually and no meaningful revenue streams, the company relies entirely on external capital markets or asset sales for survival. The expanding deficit from $39.2M in 2022 to $49.4M in 2024 signals intensifying pressure without a clear path to profitability.
About Compass Therapeutics, Inc.
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecules targeting oncology and immunology. The company serves the global market with assets in discovery and preclinical development stages, aiming to advance its pipeline of potential therapeutic candidates for serious diseases.
Analysis
Management Discussion
The company reported a net loss of $49.4M in 2024, continuing a trend of increasing losses over the past three years driven primarily by substantial research and development expenditures totaling $42.3M. Despite significant cash outflows from operations and investing activities, the firm maintained a robust cash position with $43.5M in cash equivalents and $83.2M in marketable securities, supplemented by $17.3M in financing cash flows.
Industry Overview
The biopharmaceutical industry is characterized by high barriers to entry, long development cycles, and significant regulatory hurdles, where only a small fraction of pipeline candidates succeed. Companies in this sector typically operate with negative cash flows during the research and development phases until achieving commercial milestones. Market dynamics favor firms with differentiated assets and robust financing positions capable of sustaining prolonged clinical testing periods.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $850.0K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $850.0K |
| Operating Expenses | $41.7M | $50.4M | $57.5M |
| Operating Income | $-41.7M | $-50.4M | $-56.6M |
| R&D | — | — | $42.3M |
| G&A | $11.7M | $12.2M | $15.1M |
| Stock-Based Comp | $5.3M | $6.1M | $8.6M |
| D&A | $782.0K | $699.0K | $589.0K |
| Depreciation | $800.0K | $700.0K | $600.0K |
| Other OpEx | $30.0M | $38.1M | $0 |
| Non-Operating Income | $2.4M | $7.9M | $0 |
| Interest Expense | $0 | — | — |
| Interest Income | $2.4M | $7.9M | $7.3M |
| Pre-Tax Income | $-39.2M | $-42.5M | $-56.6M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-39.2M | $-42.5M | $-56.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-39.2M | $-42.5M | $-49.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-39.2M | $-42.5M | $-49.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $194.8M | $153.9M | $132.8M |
| Cash & Equivalents | $34.9M | $24.2M | $43.5M |
| Marketable Securities | $151.7M | $128.2M | $83.2M |
| Prepaid Expenses | $8.2M | $1.4M | $6.0M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $4.9M | $3.0M | $7.7M |
| PP&E (Net) | $1.6M | $898.0K | $353.0K |
| Operating Leases | $3.0M | $1.8M | $6.7M |
| Other LT Assets | $320.0K | $320.0K | $568.0K |
| Total Assets | $199.6M | $156.9M | $140.4M |
| Current Liabilities | $16.2M | $7.8M | $8.9M |
| Accounts Payable | $3.4M | $4.1M | $2.2M |
| Current Leases | $1.1M | $1.2M | $338.0K |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $1.8M | $536.0K | $6.3M |
| LT Operating Leases | $1.8M | $536.0K | $6.3M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $18.0M | $8.3M | $15.2M |
| Shareholders' Equity | $181.6M | $148.5M | $125.2M |
| Retained Earnings | $-272.8M | $-315.3M | $-364.7M |
| AOCI | $-302.0K | $37.0K | $210.0K |
| Total L&E | $199.6M | $156.9M | $140.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-39.2M | $-42.5M | $-49.4M |
| Non-Cash Adjustments | $-4.8M | $18.3M | $-1.1M |
| Working Capital Changes | $9.9M | $-16.4M | $5.6M |
| Cash from Operations | $-34.1M | $-40.6M | $-44.9M |
| Capital Expenditures | $212.0K | $30.0K | $44.0K |
| Cash from Investing | $-151.2M | $27.0M | $46.8M |
| Cash from Financing | $75.8M | $2.9M | $17.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-109.6M | $-10.7M | $19.3M |
| Beginning Cash | $144.5M | $34.9M | $24.2M |
| Ending Cash | $34.9M | $24.2M | $43.5M |
Frequently Asked Questions
How does Compass Therapeutics, Inc. make money?
The company operates primarily through a single business segment focused on drug discovery and development, with revenue derived from minimal commercial sales or licensing arrangements totaling less than $1M annually. Financials indicate heavy allocation of resources toward research and development activities rather than diversified product lines.
What are the main risks for CMPX?
Complete dependence on the success of its drug development pipeline with no approved products generating commercial revenue; risk of dilution through equity issuances to fund operations given negative net income trends; potential failure in clinical trials leading to write-downs or cessation of programs; limited operating history and lack of sales infrastructure.
What is CMPX's competitive advantage?
Access to proprietary intellectual property in high-value oncology targets; potential for significant value creation upon successful clinical trials and regulatory approval; strong balance sheet relative to cash burn rates with substantial marketable securities providing liquidity runway.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.